Have any questions? 706-721-6582 or cts@augusta.edu
- ADXS001-04: Phase 1-2 Study of MEDI4736 Alone or In Combination with ADXS11-001 In Recurrent/Persistent or Metastatic Cervical or HPV+ Head & Neck Cancer
Clinical Trial
ADXS001-04: Phase 1-2 Study of MEDI4736 Alone or In Combination with ADXS11-001 In Recurrent/Persistent or Metastatic Cervical or HPV+ Head & Neck Cancer
This protocol will enroll participants 18 years of age and/or older who have been diagnosed with recurrent/persistent or metastic squamous or non-squamous carcinoma of the cervix or HPV+ metastic squamous carcinoma of the head and neck.
Eligibility Criteria
- INCLUSION Diagnosis of cervical or HPV+ head and neck cancer 18 years of age or older Subjects must have ability to understand and the willingness to sign informed consent EXCLUSION Subjects who are currently participating in or have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment Subjects who have a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) Subjects who have received a live vaccine within 30 days prior to the first dose of study treatment
RESEARCH. INNOVATION. DISCOVERY.